Source: Healio Coverage
September 19, 2020
1 min read

Top five ophthalmic business stories from first half of September

Source: Healio Coverage
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

One of the most-read ophthalmic business stories from the first half of September was about a large fine for Novartis and Roche/Genentech in France.

Here are some other recent ophthalmic business articles that have run on Healio/OSN so far this month.

Novartis, Roche/Genentech face major fines from French regulatory authority

Novartis and Roche/Genentech are facing a combined 444 million euros in fines from the French Competition Authority for “abusive practices” intended to sustain sales of an expensive product. Read more.

VIDEO: Tarsus works to develop Demodex blepharitis treatment

In this video, Aziz Mottiwala, newly appointed chief commercial officer for Tarsus Pharmaceuticals, discusses the company’s plans to drive the development of its therapeutic for the treatment of Demodex blepharitis. Watch more.

Orasis Pharmaceuticals raises $30 million in financing

Orasis Pharmaceuticals has closed $30 million in Series C financing to advance its eye drop candidate for the treatment of presbyopia symptoms through phase 3 clinical trials. Read more.

AMA issues CPT codes for implantation of artificial iris

The AMA has issued three CPT codes for artificial iris implantation, according to a press release from Veo Ophthalmics. Read more.

Bausch Foundation report details charitable activities

The Bausch Foundation released its inaugural activity report, detailing the contributions and work the foundation put forth in its first 2.5 years, including raising nearly $20,000 in support of the Eye Bank Association of America. Read more.